Literature DB >> 28364297

Varicella zoster virus encephalitis in a patient with a solid carcinoma: a case report.

E M Rodenburg1, F H Vermeij2, M J van den Bent3, J M Zuetenhorst4.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28364297     DOI： 10.1007/s00415-017-8466-3

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  15 in total

Review 1.  Neurologic complications of the reactivation of varicella-zoster virus.

Authors:  D H Gilden; B K Kleinschmidt-DeMasters; J J LaGuardia; R Mahalingam; R J Cohrs
Journal:  N Engl J Med       Date:  2000-03-02       Impact factor: 91.245

Review 2.  Transporters and drug-drug interactions: important determinants of drug disposition and effects.

Authors:  Jörg König; Fabian Müller; Martin F Fromm
Journal:  Pharmacol Rev       Date:  2013-05-17       Impact factor: 25.468

Review 3.  Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.

Authors:  Caroline A Lee; Meeghan A O'Connor; Tasha K Ritchie; Aleksandra Galetin; Jack A Cook; Isabelle Ragueneau-Majlessi; Harma Ellens; Bo Feng; Mitchell E Taub; Mary F Paine; Joseph W Polli; Joseph A Ware; Maciej J Zamek-Gliszczynski
Journal:  Drug Metab Dispos       Date:  2015-01-13       Impact factor: 3.922

4.  Varicella-zoster virus limbic encephalitis in an immunocompromised patient.

Authors:  P Tattevin; F Schortgen; T de Broucker; S Dautheville; M Wolff
Journal:  Scand J Infect Dis       Date:  2001

5.  Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.

Authors:  C König; M Kleber; H Reinhardt; S Knop; R Wäsch; M Engelhardt
Journal:  Ann Hematol       Date:  2013-12-07       Impact factor: 3.673

6.  Acute varicella zoster encephalitis without evidence of primary vasculopathy in a case-series of 20 patients.

Authors:  T De Broucker; A Mailles; S Chabrier; P Morand; J-P Stahl
Journal:  Clin Microbiol Infect       Date:  2011-11-15       Impact factor: 8.067

7.  Herpes zoster and human immunodeficiency virus infection.

Authors:  S P Buchbinder; M H Katz; N A Hessol; J Y Liu; P M O'Malley; R Underwood; S D Holmberg
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

8.  Infection of the central nervous system caused by varicella zoster virus reactivation: a retrospective case series study.

Authors:  Juan Carlos Lozano Becerra; Robert Sieber; Gladys Martinetti; Silvia Tschuor Costa; Pascal Meylan; Enos Bernasconi
Journal:  Int J Infect Dis       Date:  2013-04-06       Impact factor: 3.623

9.  Varicella-zoster infection in adult cancer patients. A population study.

Authors:  J J Rusthoven; P Ahlgren; T Elhakim; P Pinfold; J Reid; L Stewart; R Feld
Journal:  Arch Intern Med       Date:  1988-07

10.  Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study.

Authors:  A Hata; M Kuniyoshi; Y Ohkusa
Journal:  Infection       Date:  2011-07-29       Impact factor: 3.553
View more
  1 in total

Review 1.  Determinants of neurological syndromes caused by varicella zoster virus (VZV).

Authors:  Peter Ge Kennedy; Trine H Mogensen
Journal:  J Neurovirol       Date:  2020-06-03       Impact factor: 2.643
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.